방광경 검사 시장 보고서 : 동향, 예측, 경쟁 분석(-2035년)

Cystoscopy Market

The future of the global cystoscopy market looks promising with opportunities in the ambulatory surgical center, hospital, and urology clinic markets. The global cystoscopy market is expected to reach an estimated $452.8 Million by 2035 from $316.1 Million in 2027 with a CAGR of 10.7% from 2027 to 2035. The major drivers for this market are the increasing prevalence of urological diseases, the rising demand for minimally invasive surgeries, and the growing adoption of advanced diagnostic technologies.

• Lucintel forecasts that, within the product type category, flexible is expected to witness the highest growth over the forecast period due to more patient comfort and improved access during procedures.
• Within the end use category, ambulatory surgical centers is expected to witness the highest growth over the forecast period due to more out-patient minimally invasive urology procedures.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to greater incidence of urological disorders in the region.

Emerging Trends in Cystoscopy Market

Lucintel expects the cystoscopy market to move from hospital-based diagnosis toward earlier detection, outpatient treatment, and data-enabled surveillance during 2025-2027. Lucintel expects the market to include newer technologies for the screening of urological cancers, recurrent urinary conditions, and for a growing older adult population. New technologies and platforms are changing purchasing decisions and reimbursement and infection control continue to differentiate the market.

• Single Use: Disposable cystoscopes are reducing risks associated with scope reprocessing and hospitals are adopting these technologies. Ambu reported growth in urology in 2024 / 2025 and installations of its aScope 5 Cysto system. The FDA's device database has numerous new single use systems. The market will further change due to the infection control economics outweighing the reusable systems.
• Enhanced Imaging: Technologies such as narrow-band imaging, blue-light cystoscopy, and digital image processing that were initially used for clinical assessment of the bladder are becoming mainstream and will help expand the market over the next five years. Olympus is actively marketing NBI systems and has the dominant position in the technology. Blue light cystoscopy in conjunction with hexaminolevulinate is the only technology currently approved in the USA.
• Outpatient Migration: Due to the shorter procedure times, cystoscopy is becoming more and more common in outpatient and office based settings. This will create markets more focused on high procedure volume. In 2024, there were over 6,000 ambulatory surgical centers in the USA (ASCs) and the number is growing.
• Workflow Automation: Manufacturers are including digital documentation, image storage, and decision support within endoscopy systems. The European Association of Urology guidance calls for structured evaluations of haematuria and bladder cancer. In the next three to five years, connected workflows will decrease reporting variability and improve longitudinal surveillance.
• Regional Supply Diversification: Hospitals are procuring an expanding array of supplier options for scopes and accessories as teams seek procurement stability after the pandemic. China's 2025 medical device procurement reforms continued to promote domestic substitution and volume-based purchasing. There will be increasing competition, and prices will fall as regional manufacturing and private-label competition grow.

From 2025 to 2027, cystoscopy market growth will be less dependent on scope volumes and will be more dependent on the procedural setting, advanced imaging, and total cost of ownership. Disposable products becoming more appealing. However, the economic advantage of reusable systems remains in high-volume setting. Clinically integrated systems that improve workflow are best positioned to serve replacement needs and the emerging outpatient demand.

Recent Developments in the Cystoscopy Market

Activity in the cystoscopy market will remain strong from 2025 to 2027 as hospitals upgrade to new cystoscopy systems, urology moves more procedures to the outpatient setting, and demand for better image quality grows. Lucintel predicts competition will not be based on equipment availability, but rather on the economics of infection control, disposability, and workflow integration of cystoscopy systems. Despite the ongoing pandemic, capital investments are occurring, but more strategically and selectively as companies are beginning to introduce their systems.

• Shift To Disposable Cystoscopes: Demand for disposable cystoscopes is increasing as Ambu reported over 1.4 million single use endoscopes sold in fiscal year 2025 (Sept. 2025). This trend will dominate cystoscopy purchases for the next 3-5 years due to growing demands for ease-of-use and reduction of the burden due to reprocessing of cystoscopes.
• Upgrades To High Definition Systems: The EVIS X1 line from Olympus was upgraded in fiscal year 2025 to include 4K imaging and improved systems for use in urology. This increased demand and competition for systems with better imaging to help improve diagnosis for the detection of bladder cancer, and improved workflow/efficiency for the urology department during surgery.
• Shift from Inpatient To Outpatient Procedures: During fiscal year 2025, the payment changes from Medicare benefited the urology practice, supporting the shift of cystoscopy from inpatient to outpatient setting. This is expected to drive the purchase of systems designed for the outpatient setting, and velocity demand for more disposable accessories.
• Integration of Digital Workflows: The lead manufacturers of 2025 product offerings placed greater importance on connected towers, procedure documentation, and imaging systems that could be digitally enabled. Over the next five years, interoperability will likely affect tendering because vendors will start to gauge not just image quality but also report time, utilization, and clinical consistency.
• Infection-control Pressure: The evaluation of hospital-acquired infections in 2025 led to improvement of performance on scoping, drying, and reprocessing. The resultant economic pressure to maintain single-use cystoscopy will create a prolonged market opportunity, where the cost associated with the management of inventory will be too high due to either staffing or reprocessing constraints.

The greatest opportunities for cystoscopy growth will result from focused adoption in ambulatory urology, cancer surveillance, and acute care, rather than large replacement projects in hospitals. Where infection-control economics will result in the adoption of single-use cystoscopy, reusable systems will focus on the more academic accounts. Vendors who offer systems that provide both reliable imaging and demonstrated efficiency in workflow will experience the greatest buying interest over the next five years.

Strategic Growth Opportunities in the Cystoscopy Market

The market for cystoscopy is moving into a commercial phase with urology shifting towards outpatient diagnosis and minimally invasive procedures with a focus on early detection for cancer. Between 2024 and 2026, changing reimbursement, aging populations, innovation in devices and pressure on hospital capacity will expand demand for cystoscopies. Lucintel shows that suppliers will combine better images with workflow costs and clinical evidence.

• Office-based Flexible Systems: Shifting cystoscopy to clinics eliminates the need for an operating room; Ambu reported 1.4 million endoscopy cases performed in fiscal 2024 (November 2024). This supports growth through 2030 with an emphasis on relieving capacity constraints.
• Enhanced Imaging and AI Triage: Use of image enhanced cystoscopy can justify charge for a premium service; the American Urological Association published an update to their 2024 bladder cancer guidelines (September 2024). This will increase adoption as care providers focus on making more consistent and less vary diagnostic decisions.
• Single Use Cystoscopes: Use of disposable scopes eliminates the concern of infection control and the expense of reprocessing; Boston Scientific reported global revenue for 2024 of $16.7 billion (February 2025). This will increase where hospitals focus on the cost of each procedure and how quickly each room can be turned over.
• Women's Health Applications: Cystoscopy can used to support urogynecology, recurrent urinary-tract evaluations, and pelvic-procedure planning; in 2024, there were an estimated 11,575 births each day in the U.S. (January 2025). Wider outpatient women's health services will create more customers.
• Emerging-market Distribution: Compact systems and training models can be used by suppliers to address private hospitals in Asia, Latin America, and the Middle East. India's medical device market was expected to be worth $11 billion by 2024 (October 2024). Local partnerships will help with market adoption as stakeholder capacity in urology grows.

Suppliers should expect that winning business will not be based solely on volume of procedures. In the future, revenues will come from procedure migration, greater use of technology for performing procedures, greater use of technology for repetitive procedures and contracts for performing services. Increased procurement of technology and services will depend on the ability of suppliers to demonstrate clinical value to urologists while meeting procurement requirements for cost-savings. Suppliers of technology backed up by assurance of visualization and local service distribution with the value of technology and services should grow as the outpatient procedures increase steadily.

Cystoscopy Market Drivers and Challenges

Cystoscopy market research encompasses the interaction of multiple technological, economic, and political factors that influence diagnosis, treatment, and reimbursement, as well as the overall accessibility of healthcare. Advancements in imaging technology and growing investment in outpatient care create opportunities for this market, while high initial costs on equipment, infection control, and spatially uneven reimbursement, as well as high levels of discomfort for the patient and infection control, create barriers for this market. Market research by Lucintel identifies the interplay between innovation and infrastructure of the healthcare system as the primary determinant of market competitiveness over the next decade.

The factors responsible for driving this market include:

• Increasing Bladder-Cancer Incidence: The increasing incidence of bladder cancer drives demand for cystoscopy. The American Cancer Society reported a projected 83,190 new cases of bladder cancer in the United States in 2020, illustrating the need for continued diagnostic efforts. Since visualization of recurrence is often required for monitoring, an ongoing need for patient cystoscopy exists in the aging population and areas that are extending urological screening.
• Digital Imaging Upgrades: Better lesion detection and accuracy during procedures have been demonstrated with advanced imaging and technologies. From now to the next 3 to 5 years, improved endoscopy systems, including high-definition, narrow-band imaging (NBI), integrated documentation, and enhanced visualization, will improve procedural accuracy. Many hospitals in 2025 upgraded endoscopy systems to high-definition systems capable of 1080p, creating a market with high demand for advanced cystoscopy systems. There are many benefits to these systems, including increased ease of diagnosis, reduced burden of repeat exams, and increased physician confidence.
• Increased Outpatient Care: The urological procedures that can safely be performed in an outpatient setting are moving to the outpatient setting due to cost and convenience for patients. In 2025, flexible cystoscopy continued to dominate as an outpatient procedure. The procedure generally only took 15 to 30 minutes. The efficiency of such a care model further decreases strain on hospital resources. In the next 3 to 5 years, systems capable of outpatient procedures will increase in demand to meet the increase in desired procedures.
• Increased Demand for Minimally Invasive Diagnosis: Both patients and clinicians are interested in the least invasive, least time consuming options for diagnosis, including minimally invasive procedures to avoid surgical incisions. Flexible cystoscopy, performed with local anesthesia, is a minimally invasive substitute for surgical evaluation in the operating room. In 2025, many exams were performed without the administration of general anesthesia. It will influence future market growth of these systems due to the increasing demand for patient-centered, lower risk diagnostic options.
• Single-Use Product Adoption: The reduction of cross-contamination is an additional incentive for the use of disposable cystoscopes and has gained attention. Through 2025, the consensus within the medical community was that reusable cystoscopes would be nearly eliminated for certain procedures with significantly increased adoption of single-use systems. The scheduling of procedures would benefit from the use of single-use systems. Additionally, single-use cystoscopes provide greater control of variables. Over the next three to five years, emergency and outpatient procedures may benefit from single-use systems, while most hospitals will continue to prioritize reducing the cost of sterilization.

The challenges facing this market include:

• High Costs of Operation and Capital: Expenses for advanced cystoscopy towers, upgraded imaging systems, and contracts for systems maintenance and consumables will increase the cost of procedures. In 2025, the cost of a single-use cystoscope was approximately $100s, while the cost of reusable systems was substantially recouped through reprocessing. During this time, the high cost of single-use systems caused smaller hospitals to delay purchases. Over the next three to five years, providers will adopt a wait-and-see approach to the single-use systems until evidence is provided to support a shift from reusable systems.
• Infection-Control Complexity: Infection risk and delays to procedures remain a concern when reusable systems fail to meet quality and regulatory standards. In 2025, many facilities adopted multipart reprocessing protocols to include leak tests, manual cleaning, disinfection, drying, and storage. The next three to five years will increase costs to meet quality standards, but will also expedite the use of disposable systems and automation.
• Patient Difficulties, Financial Concerns, and The Need for Comfort and Convenience: Anxiety, pain, irritability, and the need for repeat examinations are challenges to patient acceptance of the procedure. Local anesthetic gel is currently part of most procedures. For a flexible cystoscopy procedure, the discomfort of the patient persisted for a short period of time. Economics (covering the cost of the procedure) and the need to control the cost of the procedure drive the pressure to adopt cost control measures. To overcome patient discomfort, manufacturers will have to use innovation to shorten the overall time of the procedure and ensure the comfort of patients.

Despite the increased cost of equipment, bladder cancer surveillance has driven demand for outpatient procedures. Ease of use and the introduction of newer technologies such as single-use and improved imaging devices has encouraged the growth of minimally invasive diagnostics. Most devices continue to be expensive and combined with limited reimbursement, slow the rate of adoption. The best current position in the market is held by companies that provide systems with clearer visualization along with devices that are easier to use and maintain and control costs. In the next three to five years, health care providers will pay more for technologies that provide better clinical outcomes and at the same time are easier to use. Progress in other supporting areas such as compliance and regulation will be needed to ensure market growth.

List of Cystoscopy Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies cystoscopy market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cystoscopy market companies profiled in this report include-

• Advin Health Care
• Ambu A/S
• Axess Vision Technology Ltd
• Boston Scientific Corporation
• ConMed Corporation
• Cook Medical LLC
• EndoChoice, Inc.
• Hoya Corporation
• Karl Storz SE & Co. KG
• Medtronic plc

Cystoscopy Market by Segment

The study includes a forecast for the global cystoscopy market by product type, technology, application, end use, and region.

Cystoscopy Market by Product Type [Value ($M) from 2019 to 2035]:

• Flexible
• Rigid
• Single Use

Cystoscopy Market by Technology [Value ($M) from 2019 to 2035]:

• 3D Visualization
• Digital
• Fiber Optic

Cystoscopy Market by Application [Value ($M) from 2019 to 2035]:

• Diagnostic
• Therapeutic

Cystoscopy Market by End Use [Value ($M) from 2019 to 2035]:

• Ambulatory Surgical Centers
• Hospitals
• Urology Clinics

Cystoscopy Market by Region [Value ($M) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Cystoscopy Market

Cystoscopy market activity is influenced by hospitals' shift to single-use visualization, tighter device regulation, and continued investment in minimally invasive urology. From 2025 to 2027, manufacturers will focus on high-definition imaging, digital workflow integration, and localized production In Lucintel's latest report, this will create more competition in established and new markets, respectively.

• United States: After receiving U.S. FDA clearance in 2024, Ambu began full commercialization of the aScope 5 Cysto HD in 2025. The high-definition integrated monitor system is the focus of increasing single-use investment in disposable cystoscopy. This will support adoption in outpatient urology centers over the next 3 to 5 years.
• China: Domestic medical-device substitution through centralized procurement, along with hospital purchasing reform, continued in 2025. Endoscopy investments by SonoScape and Mindray increased. The National Medical Products Administration of China approved more than 35,000 medical devices in 2024. This will help create additional low-cost, locally made cystoscopy systems."
• Germany: With German hospitals investing in integrated Operating room systems; KARL STORZ continued its investments into digital endoscopy and production. Its 2024 company report stated they employed more than 9,000 employees. With continued investment in Germany, KARL STORZ will further reinforce Germany as the manufacturing and engineering hub for reusable and digitally connected cystoscopy equipment.
• India: The Indian government's continued focus on the manufacturing of medical devices and instruments including diagnostic and endoscopy equipment, particularly Trivitron, supports the Indian government's prediction of a 10-12% CAGR for its medical devices industry up to 2030. Manufacturing cystoscopes on the Indian subcontinent will help to reduce costs and help provide urological care beyond metro hospitals.
• Japan: Olympus' continuation of its EVIS X1 endoscopy system and its digital imaging upgrades in addition to its stated research and development spending of ¥100 billion for the fiscal year 2025 will drive urological advancements with improved visualizations and improved integrations for workflow and systems in Japanese hospitals.

Features of the Global Cystoscopy Market

• Market Size Estimates: cystoscopy market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: cystoscopy market size by various segments, such as by product type, technology, application, end use, and region in terms of value ($B).
• Regional Analysis: cystoscopy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different product types, technologies, applications, end uses, and regions for the cystoscopy market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cystoscopy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the cystoscopy market by product type (flexible, rigid, and single use), technology (3D visualization, digital, and fiber optic), application (diagnostic and therapeutic), end use (ambulatory surgical centers, hospitals, and urology clinics), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Cystoscopy Market by Product Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Product Type
• 4.3 Flexible : Trends and Forecast 2019 to 2035
• 4.4 Rigid : Trends and Forecast 2019 to 2035
• 4.5 Single Use : Trends and Forecast 2019 to 2035

5. Global Cystoscopy Market by Technology

• 5.1 Overview
• 5.2 Attractiveness Analysis by Technology
• 5.3 3D Visualization : Trends and Forecast 2019 to 2035
• 5.4 Digital : Trends and Forecast 2019 to 2035
• 5.5 Fiber Optic : Trends and Forecast 2019 to 2035

6. Global Cystoscopy Market by Application

• 6.1 Overview
• 6.2 Attractiveness Analysis by Application
• 6.3 Diagnostic : Trends and Forecast 2019 to 2035
• 6.4 Therapeutic : Trends and Forecast 2019 to 2035

7. Global Cystoscopy Market by End Use

• 7.1 Overview
• 7.2 Attractiveness Analysis by End Use
• 7.3 Ambulatory Surgical Centers : Trends and Forecast 2019 to 2035
• 7.4 Hospitals : Trends and Forecast 2019 to 2035
• 7.5 Urology Clinics : Trends and Forecast 2019 to 2035

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Cystoscopy Market by Region

9. North American Cystoscopy Market

• 9.1 Overview
• 9.2 North American Cystoscopy Market by Product Type
• 9.3 North American Cystoscopy Market by End Use
• 9.4 The United States Cystoscopy Market
• 9.5 Canadian Cystoscopy Market
• 9.6 Mexican Cystoscopy Market

10. European Cystoscopy Market

• 10.1 Overview
• 10.2 European Cystoscopy Market by Product Type
• 10.3 European Cystoscopy Market by End Use
• 10.4 German Cystoscopy Market
• 10.5 French Cystoscopy Market
• 10.6 Italian Cystoscopy Market
• 10.7 Spanish Cystoscopy Market
• 10.8 The United Kingdom Cystoscopy Market

11. APAC Cystoscopy Market

• 11.1 Overview
• 11.2 APAC Cystoscopy Market by Product Type
• 11.3 APAC Cystoscopy Market by End Use
• 11.4 Chinese Cystoscopy Market
• 11.5 Indian Cystoscopy Market
• 11.6 Japanese Cystoscopy Market
• 11.7 South Korean Cystoscopy Market
• 11.8 Indonesian Cystoscopy Market

12. ROW Cystoscopy Market

• 12.1 Overview
• 12.2 ROW Cystoscopy Market by Product Type
• 12.3 ROW Cystoscopy Market by End Use
• 12.4 Middle Eastern Cystoscopy Market
• 12.5 South American Cystoscopy Market
• 12.6 African Cystoscopy Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunity by Product Type
  • 14.2.2 Growth Opportunity by Technology
  • 14.2.3 Growth Opportunity by Application
  • 14.2.4 Growth Opportunity by End Use
• 14.3 Emerging Trends in the Global Cystoscopy Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis Overview
• 15.2 Advin Health Care
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 Ambu A/S
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 Axess Vision Technology Ltd
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 Boston Scientific Corporation
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 ConMed Corporation
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.7 Cook Medical LLC
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.8 EndoChoice, Inc.
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.9 Hoya Corporation
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.10 Karl Storz SE & Co. KG
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.11 Medtronic plc
  • Company Overview
  • Cystoscopy Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us